Hoosier Cancer Research Network
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Hoosier Cancer Research Network sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Hoosier Cancer Research Network: 26 sponsored US clinical trials, none currently recruiting.
Hoosier Cancer Research Network sponsors 26 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 1 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Germ Cell Tumors, with 1 trials.
Top-decile sponsor footprint
Hoosier Cancer Research Network ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (46.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
26 total, page 1 of 1
Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary
NCT03396471
Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer
NCT02375672
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
NCT01524991
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
NCT01485874
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
NCT01186458
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
NCT01074970
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
NCT01034631
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer
NCT01232881
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
NCT00732303
Sutent + Taxol for Advanced Esophageal Cancer
NCT00730353
Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
NCT00706641
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT00613626
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT00572572
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
NCT00632541
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
NCT00537173
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
NCT00522665
A Biological Sample Collection Protocol of Women With and Without Breast Cancer
NCT00472589
A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer
NCT00317200
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT00235235
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
NCT00216151
Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT00216164
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
NCT00216047
Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
NCT00216216
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
NCT00216021
Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
NCT00216138
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
NCT00216073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 16 |
| Phase 3 | 1 |
Therapeutic Areas
How the Hoosier Cancer Research Network early-phase archive is shaped
26 indexed studies, none listed as recruiting (0% open); 12 completed (46%).
Phase mix: 1 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: Germ Cell Tumors (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Hoosier Cancer Research Network: archived-pipeline peers nationwide
Peers matched on 26 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Hoosier Cancer Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 archived trials
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Hoosier Cancer Research Network page
26 registered trials is a research-attention snapshot, not an endorsement of Hoosier Cancer Research Network or any single study.
- None of Hoosier Cancer Research Network's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Germ Cell Tumors is the condition Hoosier Cancer Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Germ Cell Tumors trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Hoosier Cancer Research Network pipeline card: 26 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.